Oikawa Kosuke, Ishida Tsuyoshi, Imamura Tetsuo, Yoshida Keiichi, Takanashi Masakatsu, Hattori Hiroyuki, Ishikawa Akio, Fujita Koji, Yamamoto Kengo, Matsubayashi Jun, Kuroda Masahiko, Mukai Kiyoshi
Department of Pathology, Tokyo Medical University, Tokyo, Japan.
Am J Surg Pathol. 2006 Mar;30(3):351-6. doi: 10.1097/01.pas.0000194043.01104.eb.
The fusion oncoproteins, TLS-CHOP and EWS-CHOP, are characteristic markers for myxoid and round cell liposarcomas (MLS/RCLS). Especially, the peptide sequence of 26 amino acids corresponding to the normally untranslated CHOP exon 2 and parts of exon 3 (5'-UTR) is a unique structure for these chimeric proteins. In this report, we have generated monoclonal antibodies against the unique peptide sequence of TLS/EWS-CHOP oncoproteins. These antibodies reacted with TLS-CHOP fusion protein, but not reacted with normal TLS and CHOP proteins by Western blot analysis. In addition, one of the antibodies also recognized the chimeric oncoprotein in archival paraffin-embedded tissue samples of MLS/RCLS. The oncoprotein was detectable by the antibody even in the paraffin-embedded tissue samples whose mRNAs were too degraded to be detected by a nested reverse transcription-polymerase chain reaction-based assay. Thus, the molecular assay using the novel antibody is expected to be one of the most sensitive diagnostic assays for MLS/RCLS.
融合癌蛋白TLS-CHOP和EWS-CHOP是黏液样和圆形细胞脂肪肉瘤（MLS/RCLS）的特征性标志物。特别是，对应于通常未翻译的CHOP外显子2和部分外显子3（5'-UTR）的26个氨基酸的肽序列是这些嵌合蛋白的独特结构。在本报告中，我们制备了针对TLS/EWS-CHOP癌蛋白独特肽序列的单克隆抗体。通过蛋白质印迹分析，这些抗体与TLS-CHOP融合蛋白反应，但不与正常的TLS和CHOP蛋白反应。此外，其中一种抗体还能识别MLS/RCLS存档石蜡包埋组织样本中的嵌合癌蛋白。即使在mRNA降解严重以至于无法通过基于巢式逆转录-聚合酶链反应的检测方法检测到的石蜡包埋组织样本中，该抗体也能检测到癌蛋白。因此，使用这种新型抗体的分子检测有望成为MLS/RCLS最灵敏的诊断检测方法之一。
